People's Daily Overseas Edition: Anti-cancer drug developed by Chinese pharmaceutical company gains market approval

The new medicine independently developed by BeiGene for two recurrent refractory lymphomas has received approval from the National Medical Products Administration (NMPA) on June 3, offering more choices for Chinese patients.

The medicine, named Brukinsa (zanubrutinib), can be used in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The medicine has received approval from the Food and Drug Administration (FDA) of the United States and is the first domestically developed anti-cancer medicine to gain approval in the US.

"The approval from the NMPA has shown that a Chinese pharmaceutical company has gained the power to offer high-quality and affordable medicine for Chinese patients," said Wu Xiaobin, general manager of BeiGene in China.

BeiGene is a biopharmaceutical company focusing on the development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It has set up a branch in China-Singapore Guangzhou Knowledge City (CSGKC) in Guangzhou's Huangpu district.

Share - WeChat